Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain

Biological Psychiatry

Volumn 55, Issue 11, 2004, Pages 1095-1102

  Maragnoli, Maria Elisabetta ^a,b   Fumagalli, Fabio ^a   Gennarelli, Massimo ^b   Racagni, Giorgio ^a,b   Riva, Marco Andrea ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Akt; depression; dopamine; Neurotrophic factor; plasticity; prefrontal cortex

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FLUOXETINE; MESSENGER RNA; OLANZAPINE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG POTENTIATION; HIPPOCAMPUS; INTRACELLULAR TRANSPORT; MALE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RIBONUCLEASE PROTECTION ASSAY; UPREGULATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BENZODIAZEPINES; BLOTTING, WESTERN; BRAIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG SYNERGISM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FIBROBLAST GROWTH FACTOR 2; FLUOXETINE; GENE EXPRESSION REGULATION; MALE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 2542463337     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.02.003     Document Type: Article

References (43)

1. Altar C.A. Neurotrophins and depression. Trends Pharmacol Sci. 20:1999;59-61
2. Brami-Cherrier K., Valjent E., Garcia M., Pages C., Hipskind R.A., Caboche J. Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons A new route to cAMP response element-binding protein phosphorylation. J Neurosci. 22:2002;8911-8921
3. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signalling A hard Akt to follow. Trends Biochem Sci. 26:2001;657-664
4. Brunet A., Datta S.R., Greenberg M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol. 11:2001;297-305
5. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657
6. Coyle J.T., Duman R.S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron. 38:2003;157-160
7. D'Onofrio M., Cuomo L., Battaglia G., Ngomba R.T., Storto M., Kingston A.E., et al. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J Neurochem. 78:2001;435-445
8. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2) An insight into an intracrine mechanism. FEBS Lett. 468:2000;6-10
9. Dono R. Fibroblast growth factors as regulators of central nervous system development and function. Am J Physiol Regul Integr Comp Physiol. 284:2003;R867-881
10. Dono R., Texido G., Dussel R., Ehmke H., Zeller R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. Embo J. 17:1998;4213-4225
11. Duman R.S. Synaptic plasticity and mood disorders. Mol Psychiatry. 7:2002;S29-34
12. Fumagalli F., Bedogni F., Maragnoli M.E., Gennarelli M., Perez J., Racagni G., et al. Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus. J Neurosci Res. 74:2003;74-80
13. Gronier B.S., Rasmussen K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neurosci Lett. 349:2003;196-200
14. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science. 286:1999;105-107
15. Huang E.J., Reichardt L.F. Neurotrophins Roles in neuronal development and function. Annu Rev Neurosci. 24:2001;677-736
16. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 76:2001;1521-1531
17. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Kanki R., et al. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res. 70:2002;274-282
18. Koch S., Perry K.W., Bymaster F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology. 46:2004;232-242
19. Lonze B.E., Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 35:2002;605-623
20. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 20:2000;9104-9110
21. Mallei A., Shi B., Mocchetti I. Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol. 61:2002;1017-1024
22. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., DenicoffK N.A.G., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 53:2003;707-742
23. McAllister A.K., Katz L.C., Lo D.C. Neurotrophins and synaptic plasticity. Annu Rev Neurosci. 22:1999;295-318
24. Molteni R., Lipska B.K., Weinberger D.R., Racagni G., Riva M.A. Developmental and stress-related changes of neurotrophic factor gene expression in an animal model of schizophrenia. Mol Psychiatry. 6:2001;285-292
25. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron. 34:2002;13-25
26. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 15:1995;7539-7547
27. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 16:1996;2365-2372
28. Palmer T.D., Markakis E.A., Willhoite A.R., Safar F., Gage F.H. Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J Neurosci. 19:1999;8487-8497
29. Paxinos G, Watson C (1996): The Rat Brain in Stereotaxic Coordinates New York: Academic Press.
30. Poo M.M. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2:2001;24-32
31. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 45:1999;1085-1098
32. Riva M.A., Molteni R., Lovati E., Fumagalli F., Rusnati M., Racagni G. Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes Comparison with fibroblast growth factor-1 and ciliary neurotrophic factor. Mol Pharmacol. 49:1996;699-706
33. Riva M.A., Molteni R., Tascedda F., Massironi A., Racagni G. Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology. 38:1999;1075-1082
34. Roceri M., Molteni R., Fumagalli F., Racagni G., Gennarelli M., Corsini G., et al. Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum. J Neurochem. 76:2001;990-997
35. Russo-Neustadt A.A., Beard R.C., Huang Y.M., Cotman C.W. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience. 101:2000;305-312
36. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci. 23:2003;349-357
37. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 158:2001;131-134
38. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 22:2002;3251-3261
39. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 60:2003;1079-1088
40. Vaccarino F.M., Schwartz M.L., Raballo R., Nilsen J., Rhee J., Zhou M., et al. Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat Neurosci. 2:1999;246-253
41. Yoshimura S., Takagi Y., Harada J., Teramoto T., Thomas S.S., Waeber C., et al. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proc Natl Acad Sci U S A. 98:2001;5874-5879
42. Zeng Z.Z., Yellaturu C.R., Neeli I., Rao G.N. 5(S)- hydroxyeicosatetraenoic acid stimulates DNA synthesis in human microvascular endothelial cells via activation of Jak/STAT and phosphatidylinositol 3-kinase/Akt signaling, leading to induction of expression of basic fibroblast growth factor 2. J Biol Chem. 277:2002;41213-41219
43. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 23:2000;250-262